Adropin is expressed in the CNS and plays a crucial role in the development of stroke. However, little is currently known about the effects of adropin on the blood-brain barrier (BBB) function after intracerebral hemorrhage (ICH). In this study, the role of adropin in collagenase-induced ICH was investigated in mice. At 1-h post-ICH, mice were administered with recombinant human adropin by intranasal. Brain water content, BBB permeability, and neurological function were measured at different time intervals. Proteins were quantified using western blot analysis, and the localizations of adropin and Notch1 were visualized via immunofluorescence staining. It is shown that adropin reduced brain water content and improved neurological functions. Adropin preserved the functionality of BBB by increasing N-cadherin expression and reducing extravasation of albumin. Moreover, in vivo knockdown of Notch1 and Hes1 both abolished the protective effects of adropin. Taken together, our data demonstrate that adropin constitutes a potential treatment value for ICH by preserving BBB and improving functional outcomes through the Notch1 signaling pathway. Keywords: adropin, blood-brain barrier, intracerebral hemorrhage, N-cadherin, Notch1.
Intracerebral hemorrhage (ICH) constitutes a severe public health issue that leads to high mortality and morbidity (Qureshi et al. 2009) , and its global incidence is increasing annually. Blood-brain barrier (BBB) disruption is the hallmark of ICHinduced brain injury. From both animal models and human studies, it has been shown that BBB disruption occurs in the acute phase after ICH (Yang et al. 1994; Lee et al. 1997; Thiex and Tsirka 2007) . The development of vasogenic brain edema from increased BBB permeability has been regarded as an important contributor to high mortality after ICH (Chen et al. 2014; Selim and Sheth 2015) . Thus, elucidating the mechanisms underlying BBB dysfunction in ICH is critical for developing methods to prevent and treat this major form of stroke (Keep et al. 2014) .
Adropin is encoded by the Energy Homeostasis Associated gene, which is expressed in the liver and brain (Kumar et al. 2008; Ganesh Kumar et al. 2012) . In the brain, the immunoreactivity of adropin showed that it is expressed in the vascular area, pia matter, neuroglial cells, Purkinje cells, granular layer, and neurons (Aydin et al. 2013; Yolbas et al. 2016 ). An in vitro study also found that adropin reduced endothelial monolayer permeability and greater cell proliferation in adropin-treated human umbilical vein and coronary artery endothelial cells (Lovren et al. 2010) . In addition, pretreatment with adropin has been demonstrated to attenuate hypoxia/low glucose-induced endothelial barrier damage in a concentration-dependent manner . However, the precise effects of adropin on BBB after ICH have not yet been evaluated.
In adropin knockout mice, it is found that adropin regulates locomotor activity and motor coordination by the NB3/Notch signaling pathway, and plays an important role in cerebellum development (Wong et al. 2014) . Treatment with adropin achieves the effect on glucose tolerance and substrate utilization with Notch1 signaling pathways in diet-induced obese mice (Gao et al. 2015) . Notch1 signaling performs an essential function in CNS development, which was conserved as an evolutionarily pathway (Ables et al. 2011) . It has been recently reported that the Notch1 signaling pathway regulates neurogenesis, neuronal networks, synaptic plasticity, learning, and memory in adult brains (Alberi et al. 2013) . In neonatal ICH study, it was shown that smad4 stabilized cerebrovascular EC-pericyte interactions by regulating the transcription of N-cadherin through associating with the Notch intracellular complex at the RBP-J binding site of the N-cadherin promoter (Li et al. 2011) . The activation of Notch results in the sequential proteolytic cleavage of the Notch receptor, which releases Notch intracellular domain (NICD) into the nucleus, which in turn activates downstream transcription of several genes, including Hes and Hey (McCright 2003; Hayward et al. 2008) .
In this study, our aim was first to test whether adropin treatment can counteract the effects of ICH-induced BBB disruption, and then determine whether it is dependent on Notch1 signaling activation, thus presenting a potential therapy for ICH.
Materials and methods

Animals
A total of 170 CD1 mice (male, 8-week-old, weight 30 AE 5 g; Charles River, Wilmington, MA, USA) were used. All of the procedures applied to animals complied with the Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee at Loma Linda University. All mice were housed in filter-top cages under controlled temperature and humidity with a 12-h light/dark cycle. Free access to food and water were supplied. The mice were arbitrary divided into different experiment groups. Animals died before endpoint were excluded and replaced with new animals. A total of two mice died because of anesthesia.
ICH models
The time-line of the study design was shown in Fig. 1 . A collagenase-induced ICH model in mouse was established as previously reported (Krafft et al. 2012 ). Briefly, ketamine (100 mg/kg) and xylazine (10 mg/kg, intraperitoneal, ip injection) were used for anesthesia for the mice. Bacterial collagenase (0.075 units, Type VII-S; Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 0.5 lL saline, and infused into the right basal ganglia at a rate of 0.1667 lL/min, using an infusion pump (Stoelting, Wood Dale, IL, USA). The needle was left for an additional 10 min to prevent possible leakage of the collagenase solution, and withdrawn slowly at a rate of 1 mm/min. The cranial burr hole was sealed with bone wax, the skin was sutured, and 0.4 mL of normal saline was injected subcutaneously. Animals were allowed to recover fully under observation. The sham operation was performed with needle insertion only.
Drug and RNA administration Adropin was dissolved in saline and tested at three different doses (0.5, 1.5, and 5.0 lg per mouse), which were administered by intranasal 1 h after ICH. Both Notch1 and Hes1 small interfering RNA (siRNA), as well as scrambled RNA, were dissolved in sterile RNAse free resuspension buffer according to the manufacturer's instructions (OriGene, Rockville, MD, USA). They were administered via intracerebroventricular injection (i.c.v.) 48 h prior to ICHinduction (Huang et al. 2015) . SiRNA or scrambled RNA (100 pmol) was delivered into the ipsilateral ventricle (1.0 mm lateral of the bregma, 2.3 mm deep) at a rate of 0.67 lL/min. After waiting for 8 min, the needle was removed over a 3 min period. The burr hole was sealed with bone wax.
Brain water content measurement Brain water content was measured at 24 and 72 h after ICH, according to previous literature (Tang et al. 2004) . Mice were decapitated under deep anesthesia, and the brains were removed immediately. Then, the brains were divided into five parts (ipsilateral and contralateral cortex, ipsilateral and contralateral basal ganglia, and cerebellum). All brain samples were weighed on an analytical microbalance (APX-60 Denver Instrument, Bohemia, NY, USA) to obtain the wet weight (WW). Samples were dried at 100°C for 48 h to obtain the dry weight (DW). Brain water content was calculated using the following formula: (WW À DW)/WW 9 100%. Neurobehavioral function assessment Neurobehavioral functions were assessed by an independent investigator who was blinded to the treatment groups. Modified Garcia, Forelimb placement, and Corner turn tests were used to evaluate neuro-deficits at 24 and 72 h after ICH. For long-term evaluation of spatial learning, a Morris Water Maze test was employed.
Evaluation of BBB permeability and hematoma volume BBB permeability evaluation involves the staining of serum albumin, known as the Evans Blue assay. Evans Blue dye extravasation assay was conducted by I.P. injection of a 4% solution of Evans Blue dye in phosphate-buffered saline (PBS) 24 h after ICH (Ma et al. 2011; Manaenko et al. 2011) . The dye was allowed to circulate for 3 h, and then the mice were transcardially perfused with cold PBS. The brains were then removed and divided into left and right hemispheres. The samples were homogenized in 1100 lL of PBS, sonicated and centrifuged separately. Trichloroacetic acid (500 lL) was added to 500 lL of the supernatant layer and incubated overnight at 4°C. Evans Blue dye absorbance was determined by spectrophotometry (Thermo Fischer Scientific Inc., Waltham, MA, USA) with wavelengths at 610 nm. Results are presented as lg of Evans Blue dye per g of brain tissue.
The hemoglobin assay was performed as previously described (Manaenko et al. 2011) . The supernatant was collected as above, and Drabkin's reagent (800 lL; Sigma, St Louis, MO, USA) was added to 200 lL of the supernatant and allowed to stand for 15 min at 25°C. Absorbance of hemoglobin was measured at 540 nm.
Western blot
Brain samples were collected at 24 h after ICH. Mice were perfused transcardially with 40 mL PBS, and proteins of the ipsilateral hemispheres were extracted by homogenizing in ristocetin-induced platelet agglutination buffer (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Western blotting was performed as previously described (Zhang et al. 2015) using primary antibodies, such as adropin (ProSci Inc., Poway, CA, USA, RRID: AB_2316252), Notch1 (Santa Cruz Biotechnology, RRID: AB_650336), NICD (Abcam, Cambridge, MA, USA, RRID: AB_306863), Hes1 (Santa Cruz Biotechnology, RRID: AB_647992), p-Akt, Akt (Cell Signaling Technology, Beverly, MA, USA, RRID AB_329825, RRID: AB_329827), ZO-1 (Santa Cruz Biotechnology, RRID: AB_628459), Claudin-5 (Santa Cruz Biotechnology, RRID: AB_2260866), N-cadherin (Santa Cruz Biotechnology, RRID: AB_647794), and Albumin (Cell Signaling Technology, RRID: AB_2225785).
Immunofluorescence staining
Immunofluorescence was performed using a previously described method (Chen et al. 2014) . Coronal slices (10 lm) were sectioned using a cryostat (CM3050S; Leica Microsystems, Wetzlar, Germany) and permeabilized with 0.3% Triton X-100 in PBS for 10-30 min. Sections were blocked with 5% donkey serum for 2 h, and incubated overnight at 4°C with primary antibodies: adropin (ProSci Inc.), Notch1 (Santa Cruz Biotechnology, RRID: AB_650336), CD13 (Abcam, AB_726095), GFAP (Abcam, RRID: AB_880202), and vWF (Abcam, RRID: AB_298501). Afterwards, sections were washed with PBS and incubated with appropriate secondary antibodies for 2 h at 25°C. Photographs were then taken using LASX software with a Leica DMi8 fluorescence microscope (Leica Microsystems).
Statistics
In this exploratory study, all tests were done two-sided. Normal distribution and similar variation between experimental groups were inspected for appropriateness before statistical tests. Parametric data was analyzed using one-way ANOVA with Tukey's post-hoc test and is expressed as mean (SD). Non-parametric data was analyzed with Kruskall-Wallis with Dunn's post-hoc tests and are presented as the median and the interquartile range (25th percentile, 75th percentile). This longitudinal data was also analyzed using repeated measures two-way ANOVA with Tukey post-hoc test. p values of less than 0.05 were considered statistically significant. On the basis of the results of the pilot preliminary study for brain water content, neurobehavioral function, Evans Blue Dye extravasation and hemoglobin assay, six animals were required to achieve 80% power to detect a difference, with a probability of p < 0.05. GraphPad Prism 6 (GraphPad Software, San Diego, CA, USA) and SPSS18.0 (IBM Corporation, Armonk, NY, USA) were used for graphing and to analyze all data.
Results
ICH transiently changed the level of adropin and Notch1 expression
The protein expression of adropin was transiently decreased at 3, 6 and 12 h, and increased at 24 h, after ICH. However, the protein expression of Notch1, NICD, and Hes1 all increased at 24 h after ICH (Fig. 2) . Double immunostaining of adropin and Notch1 with CD13 (pericytes), vWF (endothelial cells), and GFAP (astrocytes) showed that adropin and Notch1 are intensely expressed and co-localized with pericytes, endothelial cells, and astrocytes at 24 h after ICH ( Fig. 3a and b) .
Intranasal administration of adropin decreased brain edema and improved neurological functions at 24 and 72 h after ICH Three different dosages of adropin (0.5, 1.5, and 5.0 lg) were administered by intranasal 1 h after ICH. Brain water content and neurological scores were measured at 24 h after ICH. It was found that adropin at 1.5 lg decreased brain water content ( Fig. 4a ; p < 0.05, vs. ICH + vehicle), and improved Modified Garcia scores and Limb placements ( Fig. 4b and c ; p < 0.05 vs. ICH + vehicle) at 24 h after ICH; however, there was no change in the Corner turn test. The results indicated that the middle dosage of adropin was more effective as a treatment for early brain injury. Thus, this dosage was selected to further determine the effects at 72 h and to elucidate adropin's mechanism of action.
Adropin treatment significantly improved performance on Modified Garcia, Forelimb placement, and Corner turn tests at 72 h after ICH, as compared to the vehicle group (p < 0.05, Fig. 5b-d) . In the ipsilateral basal ganglia, brain water content was significantly higher in the vehicle group than the sham animals (p < 0.05 vs. sham, Fig. 5a ), and adropin treatment reduced brain edema significantly (p < 0.05, compared to ICH + vehicle, Fig. 5a ).
Adropin improved long-term neurological function at 4 weeks post-ICH
To test the effects of adropin treatment on the long-term neurological impairments neurological function was assessed by water maze at 4 weeks post-ICH. It was found that vehicle group performed significantly worse compared to sham group on water maze test. Adropin treatment showed significant memory function recovery compared to vehicle group in reduced swimming distance to platform (Fig. 6a) , reduced escape latency (Fig. 6b) , and spent more time during target quadrant (Fig. 6c) .
Adropin treatment attenuated ICH-induced disruption of BBB without having an effect on the hematoma volume The Evans Blue assay revealed significant BBB disruption at 24 h after ICH. A significant accumulation of Evans Blue dye in the ipsilateral hemisphere of vehicle-treated animals compared to sham animals was observed at 24 h after ICH (Fig. 4e , p < 0.05 vs. sham). Adropin significantly decreased ICH-induced dye accumulation (Fig. 4e , p < 0.05 vs. ICH + vehicle), but there was no effect on hematoma volume ( Figure S1 ).
Knockdown of Notch1 or Hes1 increased brain edema and brain levels of albumin, and decreased neurological scores
To investigate the potential mechanisms of adropin, Notch1 siRNA, Hes1 siRNA, or scramble siRNA were administered along with adropin treatment in ICH mice. Administrations of Notch1 siRNA and Hes1 siRNA significantly increased brain water content ( Fig. 7a ; p < 0.05 vs. ICH + Adropin + Scramble siRNA) and decreased neurological scores when compared with ICH + Adropin + Scramble siRNA group at 24 h after ICH ( Fig. 7b and c ; p < 0.05 vs. ICH + Adropin + Scramble siRNA). The level of albumin was measured by western blot at 24 h after ICH. Results from western blot indicated that adropin treatment significantly reduced the expression of albumin compared with the vehicle group after ICH ( Fig. 7e ; p < 0.05 vs. vehicle). Knockdown Notch1 or Hes1 reversed these effects of adropin ( Fig. 7 ; p < 0.05 vs. ICH + Adropin + Scramble siRNA).
Adropin treatment increased the expression of BBB Integrity through a Notch1/Hes1-dependent mechanism Administration of adropin increased the protein levels of Notch1, NICD, Hes1, phosphorylated Akt, and BBB Integrity at 24 h after ICH, compared with the vehicle group ( Fig. 8b-h ; p < 0.05 vs. vehicle). Knockdown of Notch1 with Notch1 siRNA remarkably decreased the expression of Notch1, NICD, Hes1, and p-Akt in adropin-treated animals ( Fig. 8 ; p < 0.05 vs. ICH + Adropin + Scramble siRNA). Notch1 knockdown also abolished the effect of adropin on BBB Integrity. Knockdown of Hes1 produced similar effects, reversing the adropin-induced increase in BBB Integrity, and reducing the expression of Hes1 ( Fig. 8 ; p < 0.05 vs. ICH + Adropin + Scramble siRNA).
Discussion
ICH is a fatal stroke subtype characterized by extensive blood-brain barrier disruption (Schlunk and Greenberg 2015) . Currently, there is a lack of effective treatment options for ICH. In this study, we demonstrated that administration of exogenous adropin reduced brain edema, minimized BBB disruption, and improved neurological function in mice after ICH at 24 and 72 h, also improved long-term neurological function as assessed by water maze. Adropin, with a molecular weight of 4.5 kDa, is critical for the maintenance of metabolic and non-metabolic homeostasis. However, little is currently known about its ability to cross the BBB. In the extant literature, utilizing intranasal administration has enabled many drugs to bypass the BBB, and reach the CSF and olfactory bulb via olfactory sensory neurons (Patel et al. 2009 ). Thus, in the present study, we administered Adropin intranasally. We found that Adropin expression in the brains of treated animals was increased after treatment, compared to Vehicle animals ( Figure S2 ).
BBB disruption is correlated with poor outcomes after ICH (Li et al. 2015; Shi et al. 2016) . The interaction between pericytes and endothelial cells with other cells is vital for BBB maintenance (Zhao et al. 2015) . In this study, adropin and Notch1 co-localized with pericytes, endothelial cells and astrocytes after ICH, indicating that adropin may play a significant role in maintaining BBB permeability and stability after ICH, as it interacts with its receptor on these cell types known to function in BBB preservation.
Prospective treatments that stabilize adherens junctions may reduce vasogenic brain edema, and therefore attenuate brain injury after ICH (Chen et al. 2014) . In the present study, treatment with adropin resulted in a significant reduction in brain water content, with concomitant improvements in neurological functions. We found that adropin treatment also decreased BBB permeability, as Evans Blue dye extravasation and albumin levels in the brain of adropintreated animals were reduced in comparison to vehicle. This reduction coincided with the improvement in neurobehavioral scores.
The Notch1 signaling pathway has been established as one of the downstream effectors of adropin (Wong et al. 2014; Gao et al. 2015) . In the pathogenesis of CNS disorders, the role of Notch1 signaling remains controversial. However, modulation of Notch1 signaling may restore neurogenesis Values are expressed as mean AE SD. and cognitive functioning in animal models of Alzheimer's Disease (Tanveer et al. 2012) . In addition, the Notch1/Hes1 signaling pathway participates in melatonin-mediated cardioprotective effects in both in vivo and in vitro models of myocardial ischemia-reperfusion injury (Pazar et al. 2016; Yu et al. 2016) . Notch1 is cleaved by c-secretase to release the NICD, which translocates to the nucleus and binds to a transcription factor (Gridley 2007) . Previous studies have demonstrated that administration of a Notch1 activator reduced infarct volumes and improved neurological deficits in aged rats after focal cerebral ischemia (Sun et al. 2013 ). Yet, whether Notch1 signaling is involved in the protective effects of adropin in ICH remains undetermined. We found that, after adropin treatment in ICH mice, the expression of Notch1 and NICD was significantly increased, while administering Notch1 siRNA and Hes1 siRNA reversed these effects of adropin, suggesting that the neuroprotection of adropin is mediated by the Notch1/Hes1 signaling pathway. Furthermore, Notch1 signaling is dynamically regulated during brain development and disease processes via crosstalk with numerous signaling pathways (Ables et al. 2011; Alberi et al. 2013) . Therefore, additional studies are needed to elucidate the precise mechanism of adropin in Notch1 signaling modulation after ICH. Adropin treatment also induced phosphorylation and activation of Notch1 and Akt, leading to increased BBB Integrity. N-cadherin is a candidate molecule which could be involved in endothelial commitment to blood-retina and blood-brain barrier phenotype (Gerhardt et al. 1999) . Moreover, N-cadherin is required for pericyte recruitment and vessel stabilization (Paik et al. 2004) . Previous studies have shown that knockdown of N-cadherin by siRNA resulted in increased permeability and influenced capillary tube formation in EC-pericyte co-culture systems (Li et al. 2011) . Notch1 signaling in ECs promotes adhesion by upregulating N-cadherin expression (Winkler et al. 2011) . Our findings corroborate these previous studies, further verifying adropin's role in BBB maintenance following ICH. However, there are some limitations in this study. Since we only focus on BBB function, we cannot exclude the possibility that antiapoptosis, anti-inflammatory, preservation of axonal integrity, or other effects of adropin also play neuroprotective roles after ICH. Thus, future studies are needed to investigate the other protective functions, as well as signaling mechanisms.
In conclusion, our study demonstrated that adropin was protective in the early injury stages after ICH, maintained BBB integrity, and improved functional outcomes via the Notch1/Hes1 signaling pathway. These findings indicate that adropin may constitute a particularly promising treatment for ICH.
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